NCT04018833View on ClinicalTrials.gov

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema

CompletedOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

January 1, 2012

Primary Completion Date

June 1, 2016

Study Completion Date

June 30, 2016

Conditions
Diabetic Macular EdemaDiabetic Retinopathy
Interventions
DRUG

Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]

DRUG

Aflibercept 40 MG/ML Intraocular Solution [EYLEA]

All Listed Sponsors
lead

Bernardete Pessoa MD

OTHER

NCT04018833 - Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema | Biotech Hunter | Biotech Hunter